Goldman Sachs Asks: 'Is Curing Patients a Sustainable Business Model?' - Slashdot

Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering "gene therapy" treatment: cures could be bad for business in the long run. "Is curing patients a sustainable business model?" analysts ask in an April 10 report entitled "T...

news.slashdot.org